检索结果 - Ursula Pluschnig
- Showing 1 - 5 results of 5
-
1
-
2
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study 由 Daniela Kandioler, Sebastian F. Schoppmann, Ronald Zwrtek, Sonja Kappel, Brigitte Wolf, Martina Mittlböck, I. Kührer, Michael Hejna, Ursula Pluschnig, Ahmed Ba‐Ssalamah, Fritz Wrba, Johannes Zacherl
出版 2014Artigo -
3
Ovarian function suppression and fulvestrant as endocrine therapy in premenopausal women with metastatic breast cancer 由 Rupert Bartsch, Zsuzsanna Bagó-Horváth, Anna S. Berghoff, Catharina DeVries, Ursula Pluschnig, Peter Dubsky, Margaretha Rudas, Robert M. Mader, Andrea Rottenfusser, Florian Fitzal, Michael Gnant, Christoph Zielinski, Guenther G. Steger
出版 2012Artigo -
4
Impact of anti-HER2 therapy on overall survival in HER2-overexpressing breast cancer patients with brain metastases 由 Rupert Bartsch, Anna S. Berghoff, Ursula Pluschnig, Zsuzsanna Bagó-Horváth, Peter Dubsky, Andrea Rottenfusser, Catharina DeVries, Margaretha Rudas, Florian Fitzal, Karin Dieckmann, Robert M. Mader, Michael Gnant, Christoph Zielinski, G. Steger
出版 2011Artigo -
5
Brain metastases free survival differs between breast cancer subtypes 由 Anna S. Berghoff, Zsuzsanna Bagó-Horváth, Carlie De Vries, Peter Dubsky, Ursula Pluschnig, Margaretha Rudas, Andrea Rottenfusser, Michael Knauer, Helmut Eiter, Florian Fitzal, Karin Dieckmann, Robert M. Mader, Michael Gnant, Christoph Zielinski, Guenther G. Steger, Matthias Preusser, Rupert Bartsch
出版 2012Artigo
相关主题
Breast cancer
Cancer
Internal medicine
Medicine
Oncology
Metastatic breast cancer
Chemotherapy
Trastuzumab
Anastrozole
Biochemistry
Biomarker
Brain metastasis
Capecitabine
Chemistry
Cisplatin
Colorectal cancer
Confidence interval
Esophageal cancer
Fluorouracil
Fulvestrant
Gastroenterology
Goserelin
Gynecology
Hazard ratio
Immunohistochemistry
Lapatinib
Lung cancer
Mammary gland
Metastasis
Neoadjuvant therapy